-
| CurrencyCode | USD |
|---|---|
| Exchange | NASDAQ |
| Sector | Healthcare |
| ISIN | CA60255C8850 |
| Industry | Biotechnology |
| Market Cap | 524M |
|---|---|
| PE Ratio | None |
| Target Price | 24.5 |
| Beta | 2.83 |
| Dividend Yield | None |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MNMD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025